세계의 단백질 발현 시장(-2029년) : 제품 유형(시약, 벡터, 유능세포, 장비, 소프트웨어), 서비스, 시스템 유형(포유류(CHO, HEK293), 곤충, 효모), 워크플로우, 용도(치료, 연구, 산업)별

Protein Expression Market by Product (Reagents, Vectors, Competent Cells, Instruments, Software), Services, System Type (Mammalian (CHO, HEK293), Insect, Yeast), Workflow, Application (Therapeutic, Research, Industrial) - Global Forecast to 2029

US $ 4,950 ￦ 6,972,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,366,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,479,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,085,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 단백질 발현 시장 규모는 2024년 34억 1,000만 달러에서 예측 기간 동안 연평균 7.1%의 CAGR을 기록하며 2029년에는 48억 2,000만 달러 규모로 성장할 것으로 예상됩니다.

제약 및 바이오 제약 산업의 R&D 활동 증가에 따른 생물학적 제제에 대한 수요 증가와 단백질 기반 연구를 강화하기 위한 AI 및 기계 학습의 사용 확대 등의 요인이 시장 성장을 뒷받침하고 있습니다. 또한, 맞춤형 의약품 개발로의 전환, 임상 활동의 아웃소싱 서비스 증가, 식물 기반 및 무세포 발현 시스템 사용의 중요성 증가, 합성 단백질 생산 기술 개발 등의 요인이 단백질 발현 시장의 기업들에게 성장 기회를 제공하고 있습니다.

조사 범위
조사 대상 연도	2022-2029년
기준 연도	2023년
예측 기간	2024-2029년
단위	금액(달러)
부문별	시스템 유형, 제공 구분, 워크플로우, 용도, 제품 최종사용자, 서비스 최종사용자, 지역별
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

"제공 구분별로는 제품 부문이 예측 기간 동안 가장 큰 성장률을 보일 것으로 예상"

제품 부문은 2023년 가장 높은 성장률을 기록했습니다. 단백질 기반 연구의 증가, 항체 및 백신과 같은 생물학적 제제의 승인 및 상업화 증가 등의 요인이 이 부문의 높은 성장세를 뒷받침하고 있습니다. 제품 부문에는 단백질 발현의 다양한 단계를 지원하는 시약 및 키트, 발현 벡터, 유능한 세포 및 장비가 포함됩니다. 제품 중 시약 및 키트는 단백질 발현 워크플로우의 지속적인 수요로 인해 가장 큰 규모를 보이고 있습니다. 단백질 발현 기술의 발전과 새롭고 효율적인 시약 및 키트의 출시도 이 제품 부문의 성장을 뒷받침하고 있습니다. 또한, 맞춤형 의료와 항체 및 백신과 같은 생물학적 제제에 대한 관심이 높아지면서 이들 제품에 대한 수요도 증가하고 있습니다.

"최종사용자별로 보면 예측 기간 동안 학술 연구 기관이 가장 높은 성장률을 보일 것으로 예상"

정부와 제약사의 자금 지원과 보조금 증가로 생물 및 생물의학 연구를 위한 혁신적인 연구 솔루션에 대한 수요가 증가하면서 이 부문의 높은 성장을 뒷받침하고 있습니다. 또한, 다양한 만성질환 치료를 위한 항체 및 백신과 같은 단백질 기반 치료법 개발을 위한 연구 기관 및 제약사와의 공동 연구도 증가하고 있습니다. 이러한 높은 성장세는 예측 기간 동안 지속될 것으로 예상됩니다.

"북미가 가장 크고 가장 빠른 성장 지역으로"

북미 단백질 발현 시장은 예측 기간 동안 가장 높은 성장률을 기록할 것으로 예상됩니다. 단백질 기반 치료제 개발에 중점을 둔 탄탄한 생명공학 및 제약 산업의 존재는 단백질 발현 제품 및 서비스에 대한 높은 수요로 이어지고 있습니다. 이 지역에는 주요 단백질 발현 제품 및 서비스 공급업체, 최종사용자, 첨단 연구 시설, 그리고 막대한 R&D 자금이 존재합니다. 또한, 암과 당뇨병과 같은 만성질환의 증가로 인해 단백질 기반 신약에 대한 수요가 증가하면서 효율적인 단백질 발현 기술에 대한 수요도 증가하고 있습니다. 또한, 생명과학 연구에 대한 정부의 지원과 자금 지원도 세계 단백질 발현 시장에서 북미의 큰 시장 점유율을 뒷받침하고 있습니다.

세계 단백질 발현 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 기술·특허 동향, 법·규제 환경, 사례 연구, 시장 규모 추정 및 예측, 각종 부문별·지역별·주요 국가별 상세 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 소개

제2장 조사 방법

제3장 주요 요약

제4장 주요 인사이트

제5장 시장 개요

• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 고객 비즈니스에 영향을 미치는 동향/혼란
• 가격 분석
• 공급망 분석
• 밸류체인 분석
• 생태계 분석
• 투자/자금 조달 활동
• 기술 분석
• 특허 분석
• 무역 분석
• 주요 회의와 이벤트
• 규제 분석
• Porter's Five Forces 분석
• 주요 이해관계자와 구입 기준
• AI/생성형 AI가 단백질 발현 시장에 미치는 영향

제6장 단백질 발현 시장 : 제공별

• 제품
  • 시약·키트
  • 발현 벡터
  • 컴피턴트 세포
  • 기기·소프트웨어
• 서비스

제7장 단백질 발현 시장 : 시스템 유형별

• 포유류 세포 발현 시스템
  • 차이니즈 햄스터 난소(CHO) 세포 시스템
  • 인간 태아 신장(HEK 293) 세포 시스템
  • 기타
• 원핵생물 발현 시스템
  • 대장균 시스템
  • 기타
• 곤충 세포 발현 시스템
  • 바큘로바이러스 시스템
  • 기타
• 효모 발현 시스템
  • 피치아 시스템
  • 사카로미세스 시스템
  • 기타
• 무세포 발현 시스템
• 조류 기반 발현 시스템

제8장 단백질 발현 시장 : 워크플로우별

• 클로닝·트랜스펙션
• 전사, 번역, 번역 후 변성(PTM)
• 추출, 정제, 특성 평가

제9장 단백질 발현 시장 : 용도별

• 치료
• 연구
• 산업

제10장 단백질 발현 제품 시장 : 최종사용자별

• 제약·바이오테크놀러지 기업
• 학술연구기관
• CROS·CDMOS
• 기타

제11장 단백질 발현 서비스 시장 : 최종사용자별

• 제약·바이오테크놀러지 기업
• 학술연구기관
• 기타

제12장 단백질 발현 시장 : 지역별

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동
• 아프리카

제13장 경쟁 상황

• 개요
• 주요 기업의 전략/유력 기업
• 매출 분석
• 시장 점유율 분석
• 기업 평가 매트릭스 : 주요 기업
• 기업 평가 매트릭스 : 스타트업/중소기업
• 기업 가치 평가와 재무 지표
• 브랜드/제품 비교
• 경쟁 시나리오

제14장 기업 개요

• 주요 기업
  • THERMO FISHER SCIENTIFIC INC.
  • MERCK KGAA
  • DANAHER CORPORATION
  • AGILENT TECHNOLOGIES, INC.
  • SARTORIUS AG
  • GENSCRIPT
  • TAKARA BIO INC.
  • BIO-RAD LABORATORIES, INC.
  • QIAGEN
  • CHARLES RIVER LABORATORIES
  • CORNING INCORPORATED
  • LONZA
  • FUJIFILM IRVINE SCIENTIFIC, INC.
  • SYNGENE INTERNATIONAL LIMITED
  • LGC LIMITED
  • EUROFINS SCIENTIFIC
  • AJINOMOTO CO., INC.
• 기타 기업
  • PROMEGA CORPORATION
  • SINO BIOLOGICAL, INC.
  • RAYBIOTECH, INC.
  • BIONEER CORPORATION
  • ORIGENE TECHNOLOGIES, INC.
  • NEW ENGLAND BIOLABS
  • ACCURUS BIOSCIENCES
  • ARAGEN LIFE SCIENCES LTD.
  • OXFORD EXPRESSION TECHNOLOGIES LTD
  • PROTEOGENIX INC.
  • ABEOMICS

제15장 부록

ksm

영문 목차

영문목차

The global Protein Expression market is projected to reach USD 4.82 billion in 2029 and is from USD 3.41 billion by 2024, at a CAGR of 7.1% during the forecast period. Factors such as the increasing demand for biologics supported by the rise in R&D activities in the pharmaceutical and biopharmaceutical industry and the growing use of artificial intelligence and machine learning to enhance protein-based studies are supporting the growth of the market. Moreover, factors such as the ongoing shift toward the development of personalized medicines, the rise in outsourcing services for clinical activities, the growing emphasis on the use of plant-based and cell-free expression systems, and the development of synthetic protein production technologies provide growth opportunities for players within the protein expression market. However, the high cost of protein expression reagents and instruments and the challenges associated with various expression systems are expected to restrain the growth of this market.

Scope of the Report
Years Considered for the Study	2022-2029
Base Year	2023
Forecast Period	2024-2029
Units Considered	Value (USD)
Segments	By System Type, Offerings, Workflow, Application, Product End user, Service End User, and Region
Regions covered	North America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The product segment registered the highest growth rate in the protein expression market, by offerings, during the forecast period"

In 2023, the products segment registered the highest growth rate within the protein expression market by offerings. Factors such as the rise in protein-based research and increasing approvals and commercialization of biologics, such as antibodies and vaccines are supporting the high growth of this segment. The products segment includes various reagents & kits, expression vectors, competent cells, and instruments that aid during various phases of protein expression. Reagents & kits accounted for the largest segment of the protein expression products market due to the continuous demand for these products during the protein expression workflow. Advancements in protein expression technologies and the launch of new and efficient reagents and kits are also supporting the growth of this product segment. Additionally, the rising focus on personalized medicine and biologics, such as antibodies and vaccines, is creating more demand for these products.

"The academic research institutes registered the highest growth rate in the protein expression services market, by end user, during the forecast period"

The academic research institute end user segment registered the highest growth rate within the protein expression services market by end user during the forecast period. Factors such as the increasing demand for innovative research solutions for biological and biomedical research supported by an increase in funding and grants from governments and pharmaceutical companies are supporting the high growth of this end user segment. Moreover, there is an increase in the number of collaborations between research institutes and pharmaceutical companies for the development of protein-based therapies such as antibodies and vaccines for the treatment of various chronic illnesses. This high growth is projected to continue during the forecast period.

"North America: The largest and fastest-growing region in the Protein Expression market"

The protein expression market in North America is projected to register the highest growth rate during the forecast period. This high growth is attributed to the presence of an established biotechnology and pharmaceuticals sector focusing on the development of protein-based therapies leading to a high demand for protein expression products and services. The region has key protein expression products and services suppliers and end-users as well as advanced research facilities and large R&D expenditures. In addition, the rise of chronic conditions such as cancer and diabetes has also supported the need for new protein-based drugs, increasing the demand for efficient protein expression technologies. In addition, the support and funding from the government for life sciences research also support the large market share of North America in the global protein expression market.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
• By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -5%, Middle East- 5%, Africa-5%

List of Companies Profiled in the Report:

• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• GenScript (US)
• Agilent Technologies, Inc. (US)
• Takara Bio Inc. (Japan)
• Lonza (Switzerland)
• Promega Corporation (US)
• OriGene Technologies, Inc. (US)
• Qiagen (Netherlands)
• Bio-Rad Laboratories, Inc. (US)
• Danaher Corporation (US)
• Sartorius AG (Germany)
• FUJIFILM Irvine Scientific, Inc. (Japan)
• Bioneer Corporation (South Korea)
• LGC Limited (UK)
• Sino Biological, Inc. (China)
• New England BioLabs (US)
• LifeSensors Inc. (US)
• Jena Bioscience GmbH (Germany)
• Charles River Laboratories (US)
• Corning Incorporated (US)
• Eurofins Scientific (Luxembourg)
• Ajinomoto Co., Inc. (Ajinomoto Bio-Pharma Services) (Japan)
• Syngene International Limited (India)
• Aragen Life Sciences Ltd. (India)

Research Coverage:

This report provides a detailed picture of the global Protein Expression Market. It aims at estimating the size and future growth potential of the market across different segments such as the system type, offerings, workflow, application, products end user, services end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the protein expression market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the protein expression market. Competitive analysis of upcoming startups in the protein expression market ecosystem is covered in this report.

Reasons to buy this report :

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall protein expression market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Increasing demand for biologics, Rise in R&D in pharmaceutical and biopharmaceutical industries, Growing use of artificial intelligence and machine learning, Increasing shift toward personalized medicines, and Growing outsourcing of clinical activities), restraints (High cost of protein expression offerings and the dominance of small molecules in drug development), opportunities (Growing emphasis on plant-based and cell-free expression systems, Booming markets in emerging economies, Increasing development of new synthetic protein production technologies, and Growing use of recombinant proteins), and challenges (Production cost and efficiency issues) influencing the growth of the protein expression market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the protein expression market
• Market Development: Comprehensive information about lucrative markets - the report analyses the protein expression market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the protein expression market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Agilent Technologies, Inc. (US), Sartorius AG (Germany), GenScript (US), Takara Bio Inc. (Japan), Lonza (Switzerland), among others in protein expression market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 MARKET ESTIMATION
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.3 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 PROTEIN EXPRESSION MARKET OVERVIEW
• 4.2 NORTH AMERICA: PROTEIN EXPRESSION MARKET, BY OFFERING AND COUNTRY, 2023
• 4.3 PROTEIN EXPRESSION MARKET SHARE, BY SYSTEM TYPE, 2024 VS. 2029
• 4.4 PROTEIN EXPRESSION PRODUCTS MARKET, BY END USER, 2023
• 4.5 PROTEIN EXPRESSION SERVICES MARKET, BY END USER, 2023
• 4.6 PROTEIN EXPRESSION MARKET, BY COUNTRY

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing demand for biologics
    • 5.2.1.2 Rise in R&D in pharmaceutical and biopharmaceutical industries
    • 5.2.1.3 Growing use of artificial intelligence and machine learning
    • 5.2.1.4 Increasing shift toward personalized medicines
    • 5.2.1.5 Growing outsourcing of clinical activities
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of protein expression offerings
    • 5.2.2.2 Renewed focus on small molecules in drug development
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing emphasis on plant-based and cell-free expression systems
    • 5.2.3.2 Booming market in emerging economies
    • 5.2.3.3 Increasing development of synthetic protein production technologies
    • 5.2.3.4 Growing use of recombinant proteins
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Production cost and efficiency issues
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF PROTEIN EXPRESSION PRODUCTS
  • 5.4.2 AVERAGE SELLING PRICE, BY KEY PLAYER
    • 5.4.2.1 Average selling price of system types, by key player
    • 5.4.2.2 Average selling price trend of protein expression instruments, by key player
  • 5.4.3 AVERAGE SELLING PRICE, BY REGION
    • 5.4.3.1 Average selling price of protein expression consumable products, by region
    • 5.4.3.2 Average selling price trend of protein expression instruments, by region
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT/FUNDING ACTIVITY
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Recombinant DNA technology
    • 5.9.1.2 Transfection technologies
      • 5.9.1.2.1 Reagent-based transfection
      • 5.9.1.2.2 Instrument-based transfection
      • 5.9.1.2.3 Virus-based transfection
    • 5.9.1.3 Protein expression systems
      • 5.9.1.3.1 Bacterial expression systems
      • 5.9.1.3.2 Mammalian expression systems
      • 5.9.1.3.3 Yeast expression systems
      • 5.9.1.3.4 Insect expression systems
      • 5.9.1.3.5 Cell-free expression systems
  • 5.9.2 ADJACENT TECHNOLOGIES
    • 5.9.2.1 Extraction technologies
      • 5.9.2.1.1 Non-mechanical methods
      • 5.9.2.1.2 Mechanical methods
    • 5.9.2.2 Purification and characterization technologies
      • 5.9.2.2.1 Protein purification technologies
      • 5.9.2.2.2 Protein characterization technologies
  • 5.9.3 COMPLEMENTARY TECHNOLOGIES
    • 5.9.3.1 High-throughput technologies
    • 5.9.3.2 Computation protein designing
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA
  • 5.11.2 EXPORT DATA
• 5.12 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.13 REGULATORY ANALYSIS
  • 5.13.1 REGULATORY LANDSCAPE
    • 5.13.1.1 North America
    • 5.13.1.2 Europe
    • 5.13.1.3 Emerging economies
  • 5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.14 PORTER'S FIVE FORCES ANALYSIS
  • 5.14.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.14.2 BARGAINING POWER OF SUPPLIERS
  • 5.14.3 BARGAINING POWER OF BUYERS
  • 5.14.4 THREAT OF NEW ENTRANTS
  • 5.14.5 THREAT OF SUBSTITUTES
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.15.2 BUYING CRITERIA
    • 5.15.2.1 Buying criteria for protein expression products
    • 5.15.2.2 Buying criteria for protein expression services
• 5.16 IMPACT OF AI/GEN AI ON PROTEIN EXPRESSION MARKET
  • 5.16.1 INTRODUCTION
  • 5.16.2 MARKET POTENTIAL FOR PROTEIN EXPRESSION APPLICATIONS
  • 5.16.3 AI USE CASES
  • 5.16.4 KEY COMPANIES IMPLEMENTING AI
  • 5.16.5 FUTURE OF GENERATIVE AI IN PROTEIN EXPRESSION ECOSYSTEM

6 PROTEIN EXPRESSION MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 PRODUCTS
  • 6.2.1 REAGENTS & KITS
    • 6.2.1.1 Increasing use for cloning, transfection, purification, and characterization to spur growth
  • 6.2.2 EXPRESSION VECTORS
    • 6.2.2.1 Growing production of complex proteins to propel market
  • 6.2.3 COMPETENT CELLS
    • 6.2.3.1 Increasing demand for therapeutic proteins to expedite growth
  • 6.2.4 INSTRUMENTS & SOFTWARE
    • 6.2.4.1 Increasing demand for biopharmaceuticals and personalized therapies to augment growth
• 6.3 SERVICES
  • 6.3.1 GROWING UTILIZATION OF PROTEIN EXPRESSION SERVICES FOR LARGE-SCALE PRODUCTION TO FUEL MARKET

7 PROTEIN EXPRESSION MARKET, BY SYSTEM TYPE

• 7.1 INTRODUCTION
• 7.2 MAMMALIAN CELL EXPRESSION SYSTEMS
  • 7.2.1 CHINESE HAMSTER OVARY (CHO) CELL SYSTEMS
    • 7.2.1.1 High viability, rapid growth, and improved expression levels to support growth
  • 7.2.2 HUMAN EMBRYONIC KIDNEY (HEK 293) CELL SYSTEMS
    • 7.2.2.1 Wide usage in transient transfection studies to augment growth
  • 7.2.3 OTHER MAMMALIAN CELL SYSTEMS
• 7.3 PROKARYOTIC EXPRESSION SYSTEMS
  • 7.3.1 ESCHERICHIA COLI SYSTEMS
    • 7.3.1.1 High cell density and low cost of media to stimulate growth
  • 7.3.2 OTHER PROKARYOTIC EXPRESSION SYSTEMS
• 7.4 INSECT CELL EXPRESSION SYSTEMS
  • 7.4.1 BACULOVIRUS SYSTEMS
    • 7.4.1.1 Increasing production of biologically active and functional recombinant proteins to speed up growth
  • 7.4.2 OTHER INSECT CELL EXPRESSION SYSTEMS
• 7.5 YEAST EXPRESSION SYSTEMS
  • 7.5.1 PICHIA SYSTEMS
    • 7.5.1.1 Rising production of antibody fragments, and vaccines to fuel growth
  • 7.5.2 SACCHAROMYCES SYSTEMS
    • 7.5.2.1 Increasing use of saccharomyces systems for producing heterologous proteins to accelerate growth
  • 7.5.3 OTHER YEAST EXPRESSION SYSTEMS
• 7.6 CELL-FREE EXPRESSION SYSTEMS
  • 7.6.1 INCREASING DEMAND FOR RECOMBINANT PROTEINS TO SUPPORT MARKET
• 7.7 ALGAL-BASED EXPRESSION SYSTEMS
  • 7.7.1 GROWING USE OF ALGAL-BASED EXPRESSION SYSTEMS IN ANTIBODY AND VACCINE GENERATION TO BOOST MARKET

8 PROTEIN EXPRESSION MARKET, BY WORKFLOW

• 8.1 INTRODUCTION
• 8.2 CLONING & TRANSFECTION
  • 8.2.1 CONTINUOUS REPLENISHMENT OF CONSUMABLES AND REAGENTS TO SUPPORT MARKET
• 8.3 TRANSCRIPTION, TRANSLATION, AND POST-TRANSLATIONAL MODIFICATION (PTM)
  • 8.3.1 GROWING NEED FOR FUNCTIONAL AND STABLE PROTEINS TO DRIVE MARKET
• 8.4 EXTRACTION, PURIFICATION, AND CHARACTERIZATION
  • 8.4.1 NEED TO ADHERE TO REQUIRED STANDARDS FOR SUITABLE APPLICATIONS TO DRIVE MARKET

9 PROTEIN EXPRESSION MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 THERAPEUTIC APPLICATIONS
  • 9.2.1 RISING DEMAND FOR BIOLOGICS THERAPIES TO FACILITATE GROWTH
• 9.3 RESEARCH APPLICATIONS
  • 9.3.1 GROWING INTEREST IN PROTEOMICS, GENOMICS, AND DRUG DISCOVERY TO BOOST MARKET
• 9.4 INDUSTRIAL APPLICATIONS
  • 9.4.1 INCREASING USE OF PROTEINS IN COSMETICS, TEXTILES, AND INDUSTRIAL ENZYMES TO PROMOTE GROWTH

10 PROTEIN EXPRESSION PRODUCTS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.2.1 INCREASING APPROVALS FOR BIOLOGICS TO STIMULATE GROWTH
• 10.3 ACADEMIC & RESEARCH INSTITUTES
  • 10.3.1 RISE IN GOVERNMENT AND PRIVATE FUNDING TO CONTRIBUTE TO MARKET GROWTH
• 10.4 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS & CDMOS)
  • 10.4.1 INCREASING OUTSOURCING AND COLLABORATIONS FOR PHARMACEUTICAL MANUFACTURING AND CLINICAL TRIALS TO SUSTAIN MARKET
• 10.5 OTHER END USERS

11 PROTEIN EXPRESSION SERVICES MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.2.1 INCREASING SHIFT TOWARD DRUG DEVELOPMENT OUTSOURCING TO FAVOR GROWTH
• 11.3 ACADEMIC & RESEARCH INSTITUTES
  • 11.3.1 RISING PARTNERSHIPS BETWEEN ACADEMIA AND CONTRACT RESEARCH ORGANIZATIONS TO AID GROWTH
• 11.4 OTHER END USERS

12 PROTEIN EXPRESSION MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 Growing focus on developing new therapeutics and protein-based drugs to drive market
  • 12.2.3 CANADA
    • 12.2.3.1 Increasing incidence of cancer and prevalence of public-private partnerships to sustain growth
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Increasing proteomics-based research and healthcare investments to promote growth
  • 12.3.3 UK
    • 12.3.3.1 Growing development of immunotherapies, vaccines, and proteomics to fuel market
  • 12.3.4 FRANCE
    • 12.3.4.1 Rise in funding for proteomics and genomics to spur growth
  • 12.3.5 ITALY
    • 12.3.5.1 Growing life science research supported by universities and research institutions to boost market
  • 12.3.6 SPAIN
    • 12.3.6.1 Increasing international collaborations for drug development to fuel market
  • 12.3.7 NETHERLANDS
    • 12.3.7.1 Presence of advanced infrastructure to fuel market
  • 12.3.8 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Extensive government funding in genomics and protein research to boost market
  • 12.4.3 JAPAN
    • 12.4.3.1 Increasing initiatives by government associations in life sciences sector to support market growth
  • 12.4.4 INDIA
    • 12.4.4.1 Rising collaborations between private sector and academia to facilitate growth
  • 12.4.5 AUSTRALIA
    • 12.4.5.1 Growing focus on developing new proteins and peptides to drive market
  • 12.4.6 SOUTH KOREA
    • 12.4.6.1 Increasing research & development of novel therapies to facilitate growth
  • 12.4.7 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Growing industrial investments to propel market
  • 12.5.3 MEXICO
    • 12.5.3.1 Increase in chronic diseases and robust research ecosystem to expedite growth
  • 12.5.4 ARGENTINA
    • 12.5.4.1 Rise in biotechnology and pharmaceutical research & development to augment growth
  • 12.5.5 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Strategic investments between government authorities and private players to drive market
  • 12.6.3 REST OF MIDDLE EAST
• 12.7 AFRICA
  • 12.7.1 FAVORABLE INSURANCE PROGRAMS AND CLINICAL TRIALS TO CONTRIBUTE TO MARKET GROWTH
  • 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 OVERVIEW
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2021-2024
• 13.3 REVENUE ANALYSIS, 2021-2023
• 13.4 MARKET SHARE ANALYSIS, 2023
• 13.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2023
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Region footprint
    • 13.5.5.3 Offering footprint
    • 13.5.5.4 Expression system footprint
    • 13.5.5.5 Application footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 13.6.5.1 Detailed list of key startups/SMES
    • 13.6.5.2 Competitive benchmarking of startups/SMEs
• 13.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.7.1 COMPANY VALUATION
  • 13.7.2 FINANCIAL METRICS
• 13.8 BRAND/PRODUCT COMPARISON
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT/SERVICE LAUNCHES
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 THERMO FISHER SCIENTIFIC INC.
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products and services offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product/Service launches
      • 14.1.1.3.2 Deals
      • 14.1.1.3.3 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 MERCK KGAA
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products and services offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Deals
      • 14.1.2.3.2 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 DANAHER CORPORATION
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products and services offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product/Service launches
      • 14.1.3.3.2 Deals
      • 14.1.3.3.3 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 AGILENT TECHNOLOGIES, INC.
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products and services offered
    • 14.1.4.3 MnM view
      • 14.1.4.3.1 Key strengths
      • 14.1.4.3.2 Strategic choices
      • 14.1.4.3.3 Weaknesses and competitive threats
  • 14.1.5 SARTORIUS AG
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products and services offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Deals
      • 14.1.5.3.2 Expansions
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strength
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 GENSCRIPT
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products and services offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product/Service launches
    • 14.1.6.4 MnM view
      • 14.1.6.4.1 Key strengths
      • 14.1.6.4.2 Strategic choices
      • 14.1.6.4.3 Weaknesses and competitive threats
  • 14.1.7 TAKARA BIO INC.
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products and services offered
  • 14.1.8 BIO-RAD LABORATORIES, INC.
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products and services offered
  • 14.1.9 QIAGEN
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products and services offered
  • 14.1.10 CHARLES RIVER LABORATORIES
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products and services offered
  • 14.1.11 CORNING INCORPORATED
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products and services offered
  • 14.1.12 LONZA
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products and services offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Product/Service launches
      • 14.1.12.3.2 Deals
  • 14.1.13 FUJIFILM IRVINE SCIENTIFIC, INC.
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products and services offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Product/Service launches
      • 14.1.13.3.2 Deals
      • 14.1.13.3.3 Expansions
  • 14.1.14 SYNGENE INTERNATIONAL LIMITED
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products and services offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Product/Service launches
  • 14.1.15 LGC LIMITED
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products and services offered
  • 14.1.16 EUROFINS SCIENTIFIC
    • 14.1.16.1 Business overview
    • 14.1.16.2 Products and services offered
  • 14.1.17 AJINOMOTO CO., INC.
    • 14.1.17.1 Business overview
    • 14.1.17.2 Products and services offered
• 14.2 OTHER PLAYERS
  • 14.2.1 PROMEGA CORPORATION
  • 14.2.2 SINO BIOLOGICAL, INC.
  • 14.2.3 RAYBIOTECH, INC.
  • 14.2.4 BIONEER CORPORATION
  • 14.2.5 ORIGENE TECHNOLOGIES, INC.
  • 14.2.6 NEW ENGLAND BIOLABS
  • 14.2.7 ACCURUS BIOSCIENCES
  • 14.2.8 ARAGEN LIFE SCIENCES LTD.
  • 14.2.9 OXFORD EXPRESSION TECHNOLOGIES LTD
  • 14.2.10 PROTEOGENIX INC.
  • 14.2.11 ABEOMICS

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS

관련자료